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ABSTRACT
Objectives Autoinﬂammatory diseases cause systemic
inﬂammation that can result in damage to multiple
organs. A validated instrument is essential to quantify
damage in individual patients and to compare disease
outcomes in clinical studies. Currently, there is no such
tool. Our objective was to develop a common
autoinﬂammatory disease damage index (ADDI) for
familial Mediterranean fever, cryopyrin-associated
periodic syndromes, tumour necrosis factor receptor-
associated periodic fever syndrome and mevalonate
kinase deﬁciency.
Methods We developed the ADDI by consensus
building. The top 40 enrollers of patients in the
Eurofever Registry and 9 experts from the Americas
participated in multiple rounds of online surveys to select
items and deﬁnitions. Further, 22 (parents of ) patients
rated damage items and suggested new items.
A consensus meeting was held to reﬁne the items and
deﬁnitions, which were then formally weighted in a
scoring system derived using decision-making software,
known as 1000minds.
Results More than 80% of the experts and patients
completed the online surveys. The preliminary ADDI
contains 18 items, categorised in the following eight
organ systems: reproductive, renal/amyloidosis,
developmental, serosal, neurological, ears, ocular and
musculoskeletal damage. The categories renal/
amyloidosis and neurological damage were assigned the
highest number of points, serosal damage the lowest
number of points. The involvement of (parents of )
patients resulted in the inclusion of, for example, chronic
musculoskeletal pain.
Conclusions An instrument to measure damage
caused by autoinﬂammatory diseases is developed based
on consensus building. Patients fulﬁlled a signiﬁcant role
in this process.
INTRODUCTION
Autoinﬂammatory diseases (AIDs) cover a spectrum
of diseases, which lead to chronic or recurrent
inﬂammation caused by activation of the innate
immune system, typically in the absence of high-
titre autoantibodies.1 Over recent decades, a
number of autoinﬂammatory diseases have been
recognised, genetic defects identiﬁed and the
pathogenic mechanisms elucidated.2
The four most common monogenic AIDs are
cryopyrin-associated periodic syndromes (CAPS),
familial Mediterranean fever (FMF), mevalonate
kinase deﬁciency (MKD) and tumour necrosis
factor receptor-associated periodic fever syndrome
(TRAPS). In these hereditary AIDs, chronic and
recurrent inﬂammation can lead to both acute
disease and chronic irreversible damage.3
Targeted therapy for many AIDs has become
available with blocking interleukin-1 β signalling
and/or tumour necrosis factor signalling, and for
many patients, control of active inﬂammation can
be achieved. However, organ damage may have
accrued in the prediagnostic or pretherapeutic
phase of the illness, particularly for those with
delayed diagnosis; and the control of disease activ-
ity may not be complete in every patient.4
Therefore, many patients may still develop chronic
damage from AID. This is especially true for
patients for whom effective therapy is unaffordable
or unavailable since many of these biological treat-
ments are very expensive. To date, there is no vali-
dated means of assessing the long-term burden of
AID available.
Currently, there is a patient-reported validated
tool to quantify acute inﬂammatory activity in
inherited periodic fevers (the autoinﬂammatory
disease activity index); and there is a disease severity
index for FMF, but by deﬁnition these do not assess
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long-term damage such as hearing loss, blindness and renal
failure.5–8 Damage indices for other rheumatic diseases such as
vasculitis, systemic lupus erythematosus, dermatomyositis
and juvenile idiopathic arthritis have already been developed and
validated.9–13
When devising new damage assessment tools, therapeutic
toxicity must also be considered, for example, chronic gluco-
corticoid toxicity, which can lead to cataract, growth failure and
other damaging side effects. Thus, a comprehensive damage
outcome measurement tool for AID must capture chronic and
potentially irreversible disorders of structure and function that
have risen in patients as a result of their autoinﬂammatory
disease and/or its treatment. The creation of such an index was a
stated aim of the European Union ERANET-PRIOMEDCHILD
RaDiCEA Project No. 40-41800-98-007.
The main intended purpose of the autoinﬂammatory disease
damage index (ADDI) is to analyse the outcome of patient
groups, for example, to capture and record damage in clinical
trials. In addition, it may serve as an aid to physicians in asses-
sing the needs of their patients, for example, when trying to
secure funding for biological therapies. The proposed ADDI
will be designed for use in the four more commonly encoun-
tered monogenic AIDs: FMF, CAPS, TRAPS and MKD. The
ADDI will ideally be used as one of a set of measures to capture
the disease burden for affected patients, in addition to validated
measures of disease activity, disease severity and quality of life.
METHODS
We developed the ADDI by consensus building, with online
surveys based on the Delphi method followed by a face-to-face
consensus meeting. The Delphi method is a widely accepted and
commonly used method to structurally reach consensus in a
group of experts.14
Selection of experts and patients
The top 40 enrollers to the Eurofever Registry, a European
research database for patients with AID,15 were invited to par-
ticipate as experts; another nine experts who had not partici-
pated in the European-based Eurofever Registry were recruited
from the Americas. Members of this expert group participated
in multiple online surveys and were invited for the face-to-face
consensus meeting. In close collaboration with the
Autoinﬂammatory Alliance,16 we also invited 22 patients and
parents of patients with FMF, CAPS, TRAPS or MKD to partici-
pate in an online survey, and an additional 3 patients to partici-
pate in the weighting of items, using the 1000minds
decision-making software (see below, step 4). Inclusion criteria
for selection were (1) English-speaking patients of 18 years and
older or parents of a paediatric patient with FMF, MKD, CAPS
or TRAPS; and (2) provision of fully informed signed consent
to participate in this exercise, separately for both online surveys
and interviews.
Step 1: search for possible damage items
First, a systematic literature search was performed to establish
possible damage items for FMF, MKD, CAPS and TRAPS.
Inclusion of articles to be considered was based on (1) all
studies and case series describing symptoms and complications
of more than three patients with FMF, MKD, CAPS and/or
TRAPS; (2) published in English; and (3) case reports (with
three or fewer patients) were included if they described signiﬁ-
cant new damage items. All data on the prevalence of the seque-
lae were extracted. We included all sequelae described in studies
with patients with FMF, CAPS, TRAPS and MKD, which were
likely to be caused by chronic inﬂammation or its treatment and
which persisted after resolution of inﬂammatory episodes.
Second, we screened all items scored in the Eurofever
Registry to identify new damage items not identiﬁed from the
literature review. Third, we asked patients in the ﬁrst online
survey to propose relevant new damage items. We interviewed
the patients who gave informed consent for the interviews to
try to identify other relevant damage items: we asked them spe-
ciﬁcally which complications/symptoms they most fear, and
which symptoms/complications create the greatest limitation of
daily life. Finally, we asked experts in the ﬁrst online survey for
relevant new damage items (see step 2).
Step 2: multiple rounds of online surveys with experts
Four rounds of online surveys were performed as a preparation
for the consensus meeting. Experts scored all potential damage
items for inclusion in the index, as well as the deﬁnitions and
grading of items. Experts also suggested new items, combina-
tions of items and new options for deﬁnitions/grading. If ≥80%
of the experts endorsed an item, it was included in the index. If
an item reached <50% consensus, the item was excluded. In
cases where 50–80% of the experts favoured inclusion, it was
reconsidered in the next round. These thresholds were also used
for the deﬁnitions and grading of the items.
Step 3: face-to-face consensus meeting
The 43 experts who completed one or more of the online
surveys, as well as the director of the Autoinﬂammatory Alliance
as a patient/parent representative, were invited to the consensus
meeting. The ﬁrst day the deﬁnition of damage and the inclu-
sion/deﬁnitions of the items that did not reach consensus in the
online surveys were discussed. On day 2, all items that reached
consensus in the online surveys were reﬁned. The results of the
online surveys with experts and the patient/parent surveys and
interviews were presented per item, followed by a maximum of
three voting rounds and discussion. Items and deﬁnitions with
80% consensus or more were included in the ADDI. Items with
no consensus after three voting rounds were excluded. After the
consensus meeting, we sent a ﬁnal online survey to all partici-
pants to ask whether they agreed with the items including the
deﬁnitions as proposed at the consensus meeting.
Step 4: development of a scoring system
To assign an appropriate weight to each damage item, we used
the 1000minds software in order to develop the scoring system
of the ADDI.17 1000minds is a decision-making program that
compares two items in order to grade the alternatives using the
Potentially All Pairwise RanKings of all possible Alternatives
(PAPRIKA) method.18 Brieﬂy, this method provides repeated
comparisons between two items; the expert or patient chooses
which of the two items constitutes the greater burden for
patients. Each item receives a ‘preference value’ according to the
PAPRIKA method; this reﬂects the importance of this item com-
pared with all the other items. Hence, items with the greatest
burden got the highest preference value and thus received most
points in the ADDI.
All experts and the patients were asked to complete
1000minds. We compared the means of the patient survey and
the expert survey. Differences between the overall mean and the
expert mean, as well as maximising the amount of points per
category, were discussed in a web conference with a small group
of experts. These experts were from different continents and
included both paediatric rheumatologists and rheumatologists
for adults.
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RESULTS
Identiﬁcation of damage items from literature search
and Eurofever Registry
In the literature searches, we found 1712 articles for CAPS, 632
for MKD, 2602 for FMF and 486 for TRAPS; after screening for
title and abstract, 150 articles for CAPS, 87 for MKD, 251 for
FMF and 55 for TRAPS remained. After screening for full text,
we included 36 articles for CAPS, 9 for MKD, 54 for FMF and 8
for TRAPS; in total, 49 separate damage items were extracted
from these articles (ﬁgure 1). Eight additional items extracted
from the Eurofever Registry were arterial and venous throm-
bosis, arterial aneurysm, large vessel vasculopathy, pulmonary
ﬁbrosis, lymphatic dysplasia, camptodactyly and kyphoscoliosis.
All these items were included in the online surveys with experts
and patients. No new items were selected from the case reports.
Patient/parent online survey and interviews
Twenty-two patients/parents of patients provided informed
consent to participate in the online surveys. Twenty-one patients
(95%) completed the online survey and nine of them gave
informed consent for an interview. For patient characteristics,
see table 1. Patients/parents suggested 18 new damage items,
including sexual dysfunction, chronic fatigue and chronic mus-
culoskeletal pain (table 2). The ﬁve most important damage
items according to patients were AA amyloidosis, joint damage,
vision loss, neurological damage and renal failure. All these
items were included in the preliminary ADDI.
Expert online surveys
Forty-nine experts were invited for the online surveys. The
median number (range) of included patients in the Eurofever
Registry for the 40 Eurofever experts was 49 (19-194) patients
per expert.
All rounds were completed by >80% of the experts. Experts
suggested 16 new damage items, including persistent haema-
turia, chronic fatigue and corneal opacities (table 3). Eight items
reached consensus for inclusion in the online surveys. Forty-two
items were excluded as <50% of the experts voted in favour of
the item. Examples were lymphatic dysplasia, sexual dysfunction
and glomerulonephritis. Sexual dysfunction was excluded
because experts concluded that it would be difﬁcult to prove a
causal relation with the disease (ie, whether it can be seen as
disease-associated damage); moreover, it might reﬂect disease
activity rather than damage. Seven items were discussed in the
consensus meeting as between 50% and 80% of the experts
wanted to include the item. Also, 6 of the 15 deﬁnitions
required further discussion in the consensus meeting.
Consensus meeting
On the ﬁrst day, 31 of the 43 invited participants were able to
attend the meeting. The participants discussed the items and
deﬁnitions that did not reach consensus in the online survey.
The participants excluded neuropathy, muscle weakness and
mood disorders. Consensus was reached about all deﬁnitions
that needed reconsideration. On the second day, 29 experts
Figure 1 Damage items extracted from literature for familial Mediterranean fever,3 19–71 cryopyrin-associated periodic syndromes,3 72–106 tumour
necrosis factor receptor-associated periodic fever syndrome3 67 107–112 and mevalonate kinase deﬁciency.3 113–119
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were present and reﬁned all items that already reached consen-
sus, including the deﬁnitions of these items. In the online survey
following the consensus meeting, 35 experts agreed with almost
all adaptations made in the consensus meeting. Only fatigue was
ﬁnally excluded following this survey.
Most important discussions in the consensus meeting
Inclusion of infertility and amenorrhoea did not reach consen-
sus in the online surveys, but in the consensus meeting adult
rheumatologists emphasised the great burden for patients caused
by infertility. After discussion, >80% of the participants agreed
on including these items.
Cognitive impairment was included as an addition to develop-
mental delay in the consensus meeting. As there is a variety of
rare but severe central nervous system (CNS) complications, the
participants decided to group all in one item, CNS involvement.
The group decided to replace the item abdominal adhesions
with serosal scarring in order to include all potential serosal
damage, for example, retroperitoneal ﬁbrosis. Destructive arth-
ritis and joint contractures were combined into one inclusive
item, joint restriction, as movement limitation was considered
the most important functional impact of both items.
Chronic headache was excluded because this item had a sig-
niﬁcant overlap with elevated intracranial pressure. Chronic
musculoskeletal pain and fatigue were initially included in the
consensus meeting because of the important burden for patients,
albeit with a lot of discussion. Fatigue was later excluded in the
ﬁnal online survey because the experts agreed that although
fatigue can hugely impact a patient’s life, it is difﬁcult to assess
due to its subjective nature and variable relationship with
disease activity.
Development of the scoring system
In total, 37 experts and 14 patients completed the 1000minds
survey. The means of preference values (experts and patients)
ranged from 1.5 to 7.5, in which 1.5 reﬂected the lowest and
7.5 the highest burden for patients. Experts and patients gener-
ally scored similar on the preference values (ﬁgure 2). A prelimi-
nary scoring system based on these preference values was
presented to a panel of seven representative experts and dis-
cussed in a conference call. All items with a mean preference
value of <3.5 received one point, 3.5 to 5.5 received two
points (with the exception of serosal scarring, which received
one point) and of >5.5 three points. Serosal scarring received
one point; the experts agreed in the conference call that the
consequences are less severe in comparison to other items
receiving two points. Further, a maximum of points per cat-
egory was deﬁned in order to prevent double scoring of identi-
cal items. Renal/amyloidosis received a maximum amount of six
points as amyloidosis often leads to renal damage. Also, the
neurological and musculoskeletal categories received a decreased
maximum of points because of the overlap of the items.
DISCUSSION
We developed a damage index for AID. The proposed ADDI
contains 18 items. The damage items are categorised by organ
system. All damage items are clearly deﬁned and easy to score.
Completing the ADDI should take approximately 5 min. The
ADDI will make it possible to analyse outcomes in patient
groups and compare the results of different studies, but also to
systematically measure damage in a single patient.
The ﬁrst key strength in the development of the ADDI is the
number of worldwide experts that participated. Forty European/
Middle Eastern and nine American experts were invited, with
the aim of making the ADDI a global instrument. We made the
selection of experts based on their clinical experience, which
guarantees the capability of these experts to judge the import-
ance of damage caused by AID. Furthermore, all online surveys
were completed by >80% of the experts, which is important
for both validity and acceptability of consensus statements. A
high proportion of the experts attended the consensus meeting.
The second key strength is the participation of patients and
parents of patients in all the steps that led to the development
of the ADDI. This is important to make it a widely relevant
damage index that can represent the burden for patients.
Table 1 Patient characteristics
First online
survey Interviews
1000minds
survey
Total no. of participants, n 21 9 14
Type of participant, n (%)
Patients 12 (57) 3 (33) 8 (57)
Parents 9 (43) 6 (67) 6 (43)
Age, median in years (range) 28 (2–74) 15 (6–68) 29 (6–74)
Disease, n (%)
MKD 6 (29) 1 (11) 3 (21)
TRAPS 5 (24) 3 (33) 3 (21)
CAPS 9 (43) 4 (44) 6 (43)
FMF 1 (5) 1 (11) 2 (14)
Country of residence, n (%)
Australia 2 (10) 7 (78) 1 (7)
Canada 1 (5) 2 (22) 0 (0)
Switzerland 1 (5) 0 (0) 0 (0)
Netherlands 2 (10) 0 (0) 2 (14)
USA 15 (71) 0 (0) 10 (71)
UK 0 (0) 0 (0) 1 (7)
CAPS, cryopyrin-associated periodic syndromes; FMF, familial Mediterranean fever; MKD,
mevalonate kinase deficiency; TRAPS, tumour necrosis factor receptor-associated
periodic fever syndrome.
Table 2 Items suggested by patients and experts as an addition to
the literature
Category Patient suggestions Expert suggestions
Developmental Learning difficulties
Speech developmental delay
Learning disabilities
Reproductive Amenorrhoea
Sexual dysfunction
Amenorrhoea
Neurological Memory problems
Delayed motor skill development
Hand coordination problems
Hemiplegia/quadriplegia
Mobility impairment
Gastrointestinal Irritable bowel syndrome
Portal hypertension
Malabsorption
Portal hypertension
Liver steatosis
Musculoskeletal Craniofacial deformities Facial deformities
Muscle wasting
Ocular Corneal haze
Retinitis pigmentosa
Corneal opacity
Retinitis pigmentosa
Renal Persistent haematuria
Other Social problems
Loss of future perspective
Chronic fatigue
Surgeries
Autonomic dysregulation
Chronic pain
Weight gain
Somatic growth
Chronic fatigue
Dysphonia
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Table 3 Preliminary Autoinflammatory Disease Damage Index (ADDI) including glossary of terms
Preliminary ADDI
Definition of damage: Damage is defined as persistent or irreversible change in structure or function that is present for at least 6 months. Damage items should not be scored if
they are attributed to ongoing disease activity. Damage may be the result of prior disease activity, complications of therapy or comorbid conditions that developed after the
onset of autoinflammatory disease signs and symptoms. If damage has been present for longer than 6 months, but later resolves, it should still be scored in order to capture the
damage that was present in the individual for that time period
Damage item Grading Points
Reproductive Max. 3
Sub/infertility 2
Amenorrhoea 1
Renal/amyloidosis Max. 6
Amyloidosis Limited amyloidosis
Extensive amyloidosis
2
3
Proteinuria 1
Renal insufficiency Moderate renal insufficiency
Severe renal insufficiency
2
3
Developmental Max. 3
Growth failure 2
Puberty delay 1
Serosal Max. 1
Serosal scarring 1
Neurological Max. 6
Developmental delay* 2
Cognitive impairment 3
Elevated intracranial pressure 2
Central nervous system involvement 3
Ears Max. 2
Hearing loss Moderate hearing loss of better ear
Severe hearing loss of better ear
1
2
Ocular Max. 3
Ocular involvement Mild ocular involvement of better eye
Moderate ocular involvement of better eye
Severe ocular involvement of better eye
1
2
3
Musculoskeletal Max. 4
Joint restriction 2
Bone deformity 2
Osteoporosis 1
Musculoskeletal pain 1
Glossary of terms
Infertility: A disease of the reproductive system defined by the failure to achieve a clinical pregnancy after ≥12 months of regular unprotected sexual intercourse, not due to known disorders in
the unaffected partner.
Amenorrhoea: Primary amenorrhoea: absence of menarche at the age of 16 years or absence of menarche 5 years after thelarche in a female. Secondary amenorrhoea: absence of the menses for
six consecutive months or more in a female who previously had menstrual cycles.
Limited amyloidosis: Symptomatic amyloidosis affecting one organ and confirmed by examination of tissue sections by Congo red dye or serum amyloid P component (SAP) scintigraphy.
Extensive amyloidosis: Symptomatic amyloidosis affecting more than one organ and confirmed by examination of tissue sections by Congo red dye or SAP scintigraphy.
Proteinuria: Persistent urinary protein to creatinine ratio of >20 mg/mmol in the first morning void and/or a daily protein excretion of >0.3 g/24 hours, or urine albumin to creatinine ratio of
>15 mg/mmol.
Moderate renal insufficiency: Glomerular filtration rate (GFR) between 15 and 60 mL/min/1.73 m2.
Severe renal insufficiency: GFR <15 mL/min/1.73 m2, dialysis or transplantation.
Growth failure: Defined as the presence of at least two of the three features:
– lower than the 3rd percentile height for age
– growth velocity over 6 months lower than the 3rd percentile for age
– crossing at least two centiles (5%, 10%, 25%, 50%, 75%, 90%, 95%) on growth chart
For patients older than 18 years: Pathological short stature (eg, below 3rd percentile for normal ethnic population).
Puberty delay: A Tanner stage below –2 SDs for age.
Serosal scarring: Adhesions or fibrosis affecting pericardium, pleura, peritoneum and/or retroperitoneum, supported by imaging techniques, endoscopy or surgery.
Developmental delay: Failure to reach age-appropriate developmental milestones, including language/speech, motor, social/emotional and cognitive milestones. As soon as there is any delay in
one of the development categories, this item has to be scored.*
Cognitive impairment: Requirement of special education because of cognitive impairment or IQ <70 as defined by neuropsychological assessment (eg, Wechsler Intelligence Scale for Children
(WISC)) or other age-appropriate equivalents.
Elevated intracranial pressure: Signs and/or symptoms of elevated intracranial pressure supported by appropriate techniques. †
Central nervous system involvement: Focal deficits (gross and/or fine sensorimotor), diffuse deficits (eg, memory, behaviour), seizures and spinal cord symptoms.
Moderate hearing loss: Sensorineural hearing impairment confirmed by audiometry or another age-appropriate technique without requirement of hearing aids or a cochlear implant.
Severe hearing loss: Sensorineural hearing impairment confirmed by audiometry or another age-appropriate technique requiring hearing aids or a cochlear implant.
Mild ocular involvement: Ocular damage (eg, optic nerve atrophy, elevated intraocular pressure or cataract) documented by an ophthalmologist, without visual impairment.
Moderate ocular involvement: Ocular damage (eg, optic nerve atrophy, elevated intraocular pressure or cataract) documented by an ophthalmologist, resulting in visual impairment.
Severe ocular involvement: Ocular damage (eg, optic nerve atrophy, elevated intraocular pressure or cataract) documented by an ophthalmologist, resulting in legal blindness.
Joint restriction: Fixed limitation in the normal range of motion of joints, with or without destructive arthropathy or avascular necrosis.
Bone deformity: Bone deformation or overgrowth on clinical examination and/or imaging studies.
Osteoporosis: Reduced bone mineral density with vertebral collapse and/or pathological fractures confirmed with imaging, which may include bone densitometry. Requires both evidence of
decreased bone density and fracture, ‘low bone density’ by itself is insufficient
Musculoskeletal pain: Non-inflammatory musculoskeletal pain impairing activities of daily living.
*Only for paediatric patients.
†Such as funduscopy, neuroimaging or lumbar cerebrospinal fluid (CSF) pressure measurement.
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The third key strength is the methodology used to select the
possible damage items. We screened for possible damage items
in three ways. It was evident from the literature search that
studies of long-term damage using a large sample size are
extremely scarce in autoinﬂammatory diseases. The screening of
items in the Eurofever Registry and suggestions of patients and
experts were consequently valuable in developing a comprehen-
sive set of items to asses in the online surveys.
Although many new damage items were suggested by patients
and parents of patients, it might be possible that the participat-
ing patients have not suggested all possible damage items and
they may not reﬂect the opinion of the whole patient popula-
tion. Nevertheless, their contribution strengthens the process
and resulted in consideration of previously neglected damage
items that had not been described in the literature nor men-
tioned by experts, for example, chronic pain and chronic
fatigue.
Patients with FMF were under-represented in this study
despite attempts to recruit more patients for the 1000minds
survey. Overall the amount of patients that signed informed
consent as well as the response rate to surveys was lower than
expected. Possible reasons might be the inclusion criterion for
patients to be English speaking, the difﬁculty and length of the
questionnaires and the informed consent procedure.
We chose to develop a general damage index limited to the
four most prevalent monogenetic AIDs: FMF, CAPS, TRAPS
and MKD. Based on the literature, the affected organ systems
might differ in prevalence between these diseases; nevertheless,
the ADDI will be a good tool to structurally score damage and
covers all the important damage items for these four diseases. It
would be challenging to develop the ADDI to capture damage
in all AID due to the expanding number of new ultra-rare auto-
inﬂammatory diseases and their varied clinical features. An
example of a recently discovered AID is the chronic atypical
neutrophilic dermatosis with lipodystrophy and elevated tem-
perature (CANDLE) syndrome. While CANDLE does share
some damage items with other AID, lipodystrophy is character-
istic for CANDLE,120 but is uncommon in FMF, CAPS, TRAPS
and MKD, illustrating the difﬁculty in developing a damage
index applicable to all existing and yet to be discovered AID.
Common non-speciﬁc symptoms like chronic headache,
fatigue and chronic musculoskeletal pain gave rise to intense dis-
cussions. Ultimately, only chronic musculoskeletal pain is
included in the preliminary ADDI. Although patients considered
these items as important in the surveys and interviews, experts
thought that these items were difﬁcult to assess objectively in
daily clinical practice and found it hard to deﬁne whether these
items actually reﬂected disease damage rather than ongoing
disease activity. Nonetheless, experts acknowledged that these
items have a considerable impact on the quality of life. In the
future, these items might be better included in a different tool,
for example, with speciﬁc items to measure quality of life.
Another difﬁculty in the development of the ADDI was the
inﬂuence of comorbidities on the damage in AID patients. This
is a common issue for all damage indices. For example, neuro-
logical impairment can be caused by the AID or by an unrelated
Figure 2 Scoring of the preference values from experts (black) and patients (grey), derived from the 1000minds decision-making software.
A higher preference value means a higher burden for patients. The preference values range from 1.5 to 7.5, all items with a weighted mean
preference value of <3.5 received one point in the Autoinﬂammatory Disease Damage Index (ADDI), and of >5.5 three points.
6 ter Haar NM, et al. Ann Rheum Dis 2016;0:1–10. doi:10.1136/annrheumdis-2016-210092
Clinical and epidemiological research
group.bmj.com on March 27, 2017 - Published by http://ard.bmj.com/Downloaded from 
stroke. It is very hard to distinguish whether it is caused by
independent comorbidities or the disease itself, even though we
only include damage items that arose after the onset of symp-
toms of the AID.
In the near future, the preliminary ADDI will be validated using
patient cases of FMF, CAPS, TRAPS and MKD. By this effort, we
will be able to assess the validity of the ADDI in total and for the
individual diseases. Furthermore, we will analyse the speciﬁcity of
the ADDI items (eg, whether the damage items are not inﬂuenced
by disease activity) and the grading system. Prospective validation
in longitudinal cohorts will then be needed to investigate respon-
siveness to change over time and correlation with the burden of
disease-associated damage to daily life.
In conclusion, we developed the ADDI, a universal instru-
ment to measure persisting damage caused by chronic inﬂamma-
tion in the autoinﬂammatory diseases FMF, CAPS, TRAPS and
MKD. This ADDI is based on consensus building with experts
from around the world; patients and parents of patients fulﬁlled
a signiﬁcant role in this process.
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